A PILOT STUDY OF SEQUENTIAL, NON-MYELOABLATIVE HLA-IDENTICAL SIBLING DONOR ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWED BY IV TEMSIROLIMUS IN PATIENTS WITH ADVANCED, TKI-REFRACTORY CLEAR-CELL RENAL CELL CANCER.
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2012
At a glance
- Drugs Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms AlloTor
- 15 Dec 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 02 Aug 2011 New trial record